161. Familial benign chronic pemphigus Clinical trials / Disease details


Clinical trials : 5 Drugs : 9 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 24

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05007223
(ClinicalTrials.gov)
May 8, 20205/8/2021Skin Microbiome Profile in Hailey-Hailey DiseaseCharacterization and Analysis of the Skin Microbiome in Hailey-Hailey DiseaseHailey-Hailey DiseaseDrug: DoxycyclineGangnam Severance HospitalNULLCompleted19 YearsN/AAll18Korea, Republic of
2EUCTR2018-000373-80-FR
(EUCTR)
24/05/201813/03/2018A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey DiseaseA Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101 Darier’s Disease or Hailey-Hailey Disease
MedDRA version: 20.0;Level: LLT;Classification code 10011860;Term: Darier's disease;System Organ Class: 100000004850
MedDRA version: 20.1;Classification code 10019029;Term: Hailey-Hailey disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: LX3305 250 mg capsule
Product Code: LX3305
INN or Proposed INN: None
Other descriptive name: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime
Dermecular Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
40Phase 1;Phase 2France
3NCT02782702
(ClinicalTrials.gov)
September 201520/5/2016Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey DarierHailey-Hailey Disease;Darier DiseaseDrug: Botulism Toxin TreatmentUniversity Hospital, ToulouseNULLCompleted18 YearsN/AAll30Phase 1NULL
4EUCTR2013-004562-33-IT
(EUCTR)
17/12/201318/11/2013PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTSPHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS SYMPTOMATIC HHD PATIENTS
MedDRA version: 16.1;Level: LLT;Classification code 10019029;Term: Hailey-Hailey disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: SCENESSE
Product Name: SCENESSE
ISTITUTI FISIOTERAPICI OSPITALIERINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Phase 2Italy
5JPRN-UMIN000010191
2013/04/0101/04/2013The examination of the clinical response of celecoxib in Darier's disease and Hailey-Hailey diseaseThe examination of the clinical response of celecoxib in Darier's disease and Hailey-Hailey disease - The examination of the clinical response of celecoxib in Darier's disease and Hailey-Hailey disease Drier's disease Hailey-Hailey diseasecelecoxibJuntendo university gradurate school of medicineNULLPending20years-oldNot applicableMale and Female10Not selectedJapan